Home
    Disclaimer
    Ethchlorvynol molecular structure

    Ethchlorvynol Stats & Data

    Placidyl Ethchlorvnol placdyl
    PubChem
    MW144.60
    FormulaC7H9ClO
    LogP1.5
    IUPAC(E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol
    InChIKeyZEHYJZXQEQOSON-AATRIKPKSA-N
    Chemical Class Cannabinoid
    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    Protein binding 35-50% State Liquid

    Description

    Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

    Mechanism of Action

    Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

    Pharmacodynamics

    Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.

    Metabolism

    About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

    Absorption

    Rapidly absorbed from gastrointestinal tract.

    Indication

    Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.

    Half-life

    Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.

    Toxicity

    PubChem DrugBank

    Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open.

    Carcinogenicity

    No indication of carcinogenicity to humans (not listed by IARC).

    Toxicity (DrugBank)

    Symptoms of overdose include thrombocytopenia.

    Health effects (PubChem excerpts)

    They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 3d Half tolerance 21d Baseline ~28d

    Experience Report Analysis

    Erowid
    2 Reports
    1999–1999 Date Range
    1 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Form / Preparation

    Most common forms and preparations reported

    ← Back to Ethchlorvynol